Interest in psychedelic-assisted therapy has grown dramatically over the past several years, but one of the biggest misconceptions is that ketamine, MDMA, and psilocybin are essentially the same treatment.
They are not.
Although these therapies are often discussed together, they differ in their legal status, the conditions researchers are studying, how treatment sessions are structured, and what role they may ultimately play in mental health care.
If you’re exploring psychedelic therapy in California, understanding these differences can help you better interpret current research and the treatment options that are available today.
Three Therapies With Three Different Roles
Ketamine, MDMA, and psilocybin all fall under the broader conversation surrounding psychedelic-assisted therapy, but each has followed a different scientific and clinical path.
Today:
- Ketamine therapy is legally available through licensed medical providers for appropriate patients.
- MDMA-assisted therapy remains primarily available through clinical research while scientists continue studying its role in trauma treatment.
- Psilocybin-assisted therapy also remains largely limited to research settings as studies continue evaluating its potential across several psychiatric conditions.
While all three involve psychotherapy to varying degrees, researchers are investigating them for different reasons.
Ketamine Therapy: Currently Available in Clinical Practice
Ketamine is unique because it is already being used in medical settings today.
Originally developed as an anesthetic, ketamine has become an important treatment option for certain individuals experiencing treatment-resistant depression and other psychiatric conditions under appropriate medical supervision.
Researchers have studied ketamine for:
- Treatment-resistant depression
- Major depressive disorder
- Suicidal ideation
- Certain anxiety disorders
- Some chronic pain conditions
Treatment may involve IV infusions, intramuscular injections, nasal spray, or oral medications depending on the provider and treatment plan.
Some clinics focus primarily on medication administration, while others combine ketamine with psychotherapy through ketamine-assisted psychotherapy (KAP).
To learn more, visit our guide to Ketamine Therapy in California.
MDMA Therapy: Research Focused Primarily on PTSD
Among emerging psychedelic therapies, MDMA has become most closely associated with PTSD research.
Unlike ketamine, MDMA is not currently available as routine clinical treatment outside approved research settings.
Researchers have primarily studied MDMA-assisted therapy for:
- Post-traumatic stress disorder
- Military veterans
- First responders
- Survivors of assault
- Survivors of other significant traumatic experiences
Rather than functioning as a medication taken regularly, MDMA is studied as one component of an intensive psychotherapy model that generally includes:
- Psychological screening
- Preparation sessions
- One or more medication-assisted therapy sessions
- Follow-up integration therapy
Researchers believe the therapeutic process surrounding MDMA is just as important as the medication itself.
You can learn more in our MDMA Therapy in California guide.
Psilocybin Therapy: Expanding Research Beyond Trauma
Psilocybin research has expanded rapidly over the past decade, but its primary focus differs from MDMA.
Rather than concentrating on PTSD, researchers have largely investigated psilocybin for:
- Major depressive disorder
- Treatment-resistant depression
- Anxiety
- End-of-life psychological distress
- Substance use disorders
- Obsessive-compulsive disorder
Researchers continue exploring whether psilocybin-assisted therapy may help individuals process emotions, develop psychological flexibility, and improve symptoms when combined with structured psychotherapy.
Like MDMA, psilocybin therapy remains largely confined to research settings while additional studies continue.
Our Psilocybin Therapy in California guide explains the current state of research and availability.
Session Lengths and Treatment Experience
Although all three therapies involve careful planning and professional supervision, the treatment experience differs considerably.
Ketamine
Ketamine sessions are generally the shortest.
Depending on the treatment protocol, patients often spend approximately one to two hours at the clinic. Many providers recommend a series of treatments over several weeks.
MDMA
MDMA-assisted therapy sessions are significantly longer.
Research protocols commonly involve sessions lasting six to eight hours or more with therapists present throughout the experience. Preparation before treatment and integration afterward are considered essential parts of care.
Psilocybin
Psilocybin sessions are also lengthy.
Participants typically spend much of the day in a carefully supervised therapeutic environment before returning for follow-up integration sessions in the days and weeks that follow.
Different Legal Status
One of the most important differences is current availability.
Ketamine
Ketamine can be legally prescribed and administered by licensed medical providers for appropriate clinical indications.
MDMA
MDMA-assisted therapy remains largely limited to approved research studies while researchers continue evaluating safety and effectiveness.
Psilocybin
Psilocybin-assisted therapy also remains primarily available through clinical trials and regulated research settings.
As research continues and regulations evolve, access to these therapies may change.
Different Therapeutic Models
Another important distinction is how treatment is delivered.
Ketamine treatment often follows a medical model that may include medication management with or without psychotherapy depending on the clinic.
MDMA research places psychotherapy at the center of treatment. Preparation, medication sessions, and integration therapy are all considered essential components.
Psilocybin research follows a similar framework, emphasizing preparation before treatment and integration afterward rather than viewing the medication experience as the treatment itself.
Across all three therapies, researchers generally agree that careful patient selection, clinical oversight, and ongoing therapeutic support remain essential.
Why These Therapies Shouldn’t Be Considered Interchangeable
Because ketamine, MDMA, and psilocybin are frequently discussed together, it’s easy to assume they work similarly.
In reality, they differ in:
- Current legal availability
- Conditions being studied
- Clinical evidence
- Session length
- Therapeutic structure
- Mechanism of action
- Treatment goals
Someone exploring treatment-resistant depression may encounter very different research than someone seeking care for PTSD or trauma-related conditions.
Understanding these distinctions helps patients have more informed conversations with healthcare professionals while following developments in this rapidly evolving field.
Looking Ahead
Research into psychedelic-assisted therapies continues to expand, and each treatment may ultimately serve a different role within mental health care.
Today:
- Ketamine is the only therapy of the three that is broadly available through licensed medical providers.
- MDMA remains most closely associated with trauma-focused psychotherapy and PTSD research.
- Psilocybin is being studied across a wider range of conditions, particularly depression, anxiety, and end-of-life psychological distress.
As additional clinical trials are completed and new evidence emerges, researchers hope to better understand where each therapy may fit alongside existing evidence-based mental health treatments.